Conatus Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Conatus Pharmaceuticals Inc.
Vanguard Total Stock Market Index Fund
765,014
2.54%
0
0%
07/31/2018
AXA Framlington Biotech Fund
437,979
1.46%
0
0.35%
02/28/2018
Vanguard Extended Market Index Fund
367,168
1.22%
0
0%
07/31/2018
Vanguard Variable Insurance - Small Company Growth Portfolio
152,005
0.51%
0
0.04%
06/30/2018
BlackRock Small Cap Growth Equity Portfolio
134,713
0.45%
0
0.09%
05/31/2018
CREF Stock Account
123,160
0.41%
-71,800
0%
03/31/2018
Fidelity Spartan Extended Market Index Fund
122,869
0.41%
0
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
113,000
0.38%
0
0.14%
12/31/2017
Fidelity Small Cap Enhanced Index Fund
96,273
0.32%
-12,221
0.06%
02/28/2018
BlackRock Disciplined Small Cap Core Fund
88,198
0.28%
21,856
0.1%
06/29/2018
| Address |
16745 West Bernardo Drive
San Diego California 92127
United States
|
|
Employees
|
- |
| Website |
http://www.conatuspharma.com |
| Updated |
07/08/2019 |
| Conatus Pharmaceuticals, Inc. engages in the development and commercialization of medicines for the treatment of liver diseases. It focuses in development of emricasan, an active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease, which reduce the activities of human caspases. The company was founded by Alfred P. |
